Incidence of acute kidney injury among patients treated with piperacillin-tazobactam or meropenem in combination with vancomycin

W. Cliff Rutter, David S. Burgess

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Acute kidney injury (AKI) increases during empirical antimicrobial therapy with the combination of piperacillin-tazobactam (TZP) and vancomycin (VAN) compared to the number of incidences with monotherapy or the combination of cefepime and VAN. Limited data regarding the impact of meropenem (MEM) combined with VAN exist. This study examined the AKI incidence among patients treated with MEM plus VAN (MEMVAN) or TZPVAN. Data were collected from the University of Kentucky Center for Clinical and Translational Science Enterprise Data Trust from September 2007 through October 2015. Adults without previous renal disease who received MEMVAN or TZPVAN for at least 2 days were included. AKI was assessed using risk, injury, failure, loss, and end-stage (RIFLE) criteria. Inverse probability of treatment weighting was utilized to control for differences between groups. In total, 10,236 patients met inclusion criteria, with 9,898 receiving TZPVAN and 338 receiving MEMVAN. AKI occurred in 15.4% of MEMVAN patients and in 27.4% of TZPVAN patients (P 0.001). TZPVAN was associated with increased AKI compared to the level with MEMVAN (odds ratio [OR], 2.53; 95% confidence interval [CI], 1.82 to 3.52), after controlling for confounders. Use of MEMVAN should be considered an appropriate alternative therapy to TZPVAN if nephrotoxicity is a major concern. The results of this study demonstrate that judicial use of TZPVAN for empirical coverage of infection is needed.

Original languageEnglish (US)
Article numbere00264-18
JournalAntimicrobial Agents and Chemotherapy
Volume62
Issue number7
DOIs
StatePublished - Jul 1 2018
Externally publishedYes

Fingerprint

meropenem
Vancomycin
Acute Kidney Injury
Incidence
Complementary Therapies
Odds Ratio
tazobactam drug combination piperacillin
Confidence Intervals
Kidney

Keywords

  • Acute kidney injury
  • Beta-lactams
  • Combination therapy
  • Vancomycin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Incidence of acute kidney injury among patients treated with piperacillin-tazobactam or meropenem in combination with vancomycin. / Rutter, W. Cliff; Burgess, David S.

In: Antimicrobial Agents and Chemotherapy, Vol. 62, No. 7, e00264-18, 01.07.2018.

Research output: Contribution to journalArticle

@article{6786d986b6d843ab9a5e72694fe02ca7,
title = "Incidence of acute kidney injury among patients treated with piperacillin-tazobactam or meropenem in combination with vancomycin",
abstract = "Acute kidney injury (AKI) increases during empirical antimicrobial therapy with the combination of piperacillin-tazobactam (TZP) and vancomycin (VAN) compared to the number of incidences with monotherapy or the combination of cefepime and VAN. Limited data regarding the impact of meropenem (MEM) combined with VAN exist. This study examined the AKI incidence among patients treated with MEM plus VAN (MEMVAN) or TZPVAN. Data were collected from the University of Kentucky Center for Clinical and Translational Science Enterprise Data Trust from September 2007 through October 2015. Adults without previous renal disease who received MEMVAN or TZPVAN for at least 2 days were included. AKI was assessed using risk, injury, failure, loss, and end-stage (RIFLE) criteria. Inverse probability of treatment weighting was utilized to control for differences between groups. In total, 10,236 patients met inclusion criteria, with 9,898 receiving TZPVAN and 338 receiving MEMVAN. AKI occurred in 15.4{\%} of MEMVAN patients and in 27.4{\%} of TZPVAN patients (P 0.001). TZPVAN was associated with increased AKI compared to the level with MEMVAN (odds ratio [OR], 2.53; 95{\%} confidence interval [CI], 1.82 to 3.52), after controlling for confounders. Use of MEMVAN should be considered an appropriate alternative therapy to TZPVAN if nephrotoxicity is a major concern. The results of this study demonstrate that judicial use of TZPVAN for empirical coverage of infection is needed.",
keywords = "Acute kidney injury, Beta-lactams, Combination therapy, Vancomycin",
author = "Rutter, {W. Cliff} and Burgess, {David S.}",
year = "2018",
month = "7",
day = "1",
doi = "10.1128/AAC.00264-18",
language = "English (US)",
volume = "62",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "7",

}

TY - JOUR

T1 - Incidence of acute kidney injury among patients treated with piperacillin-tazobactam or meropenem in combination with vancomycin

AU - Rutter, W. Cliff

AU - Burgess, David S.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Acute kidney injury (AKI) increases during empirical antimicrobial therapy with the combination of piperacillin-tazobactam (TZP) and vancomycin (VAN) compared to the number of incidences with monotherapy or the combination of cefepime and VAN. Limited data regarding the impact of meropenem (MEM) combined with VAN exist. This study examined the AKI incidence among patients treated with MEM plus VAN (MEMVAN) or TZPVAN. Data were collected from the University of Kentucky Center for Clinical and Translational Science Enterprise Data Trust from September 2007 through October 2015. Adults without previous renal disease who received MEMVAN or TZPVAN for at least 2 days were included. AKI was assessed using risk, injury, failure, loss, and end-stage (RIFLE) criteria. Inverse probability of treatment weighting was utilized to control for differences between groups. In total, 10,236 patients met inclusion criteria, with 9,898 receiving TZPVAN and 338 receiving MEMVAN. AKI occurred in 15.4% of MEMVAN patients and in 27.4% of TZPVAN patients (P 0.001). TZPVAN was associated with increased AKI compared to the level with MEMVAN (odds ratio [OR], 2.53; 95% confidence interval [CI], 1.82 to 3.52), after controlling for confounders. Use of MEMVAN should be considered an appropriate alternative therapy to TZPVAN if nephrotoxicity is a major concern. The results of this study demonstrate that judicial use of TZPVAN for empirical coverage of infection is needed.

AB - Acute kidney injury (AKI) increases during empirical antimicrobial therapy with the combination of piperacillin-tazobactam (TZP) and vancomycin (VAN) compared to the number of incidences with monotherapy or the combination of cefepime and VAN. Limited data regarding the impact of meropenem (MEM) combined with VAN exist. This study examined the AKI incidence among patients treated with MEM plus VAN (MEMVAN) or TZPVAN. Data were collected from the University of Kentucky Center for Clinical and Translational Science Enterprise Data Trust from September 2007 through October 2015. Adults without previous renal disease who received MEMVAN or TZPVAN for at least 2 days were included. AKI was assessed using risk, injury, failure, loss, and end-stage (RIFLE) criteria. Inverse probability of treatment weighting was utilized to control for differences between groups. In total, 10,236 patients met inclusion criteria, with 9,898 receiving TZPVAN and 338 receiving MEMVAN. AKI occurred in 15.4% of MEMVAN patients and in 27.4% of TZPVAN patients (P 0.001). TZPVAN was associated with increased AKI compared to the level with MEMVAN (odds ratio [OR], 2.53; 95% confidence interval [CI], 1.82 to 3.52), after controlling for confounders. Use of MEMVAN should be considered an appropriate alternative therapy to TZPVAN if nephrotoxicity is a major concern. The results of this study demonstrate that judicial use of TZPVAN for empirical coverage of infection is needed.

KW - Acute kidney injury

KW - Beta-lactams

KW - Combination therapy

KW - Vancomycin

UR - http://www.scopus.com/inward/record.url?scp=85049000063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049000063&partnerID=8YFLogxK

U2 - 10.1128/AAC.00264-18

DO - 10.1128/AAC.00264-18

M3 - Article

VL - 62

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 7

M1 - e00264-18

ER -